Читать книгу The Peripheral T-Cell Lymphomas - Группа авторов - Страница 65

One of the more exciting areas in PTCL research involves the development of combination therapies that target, either in part or in unison, some of the dysregulated epigenetic biology discussed above. While these experiences are discussed in more detail in other chapters (and is summarized here in Table 3.3), it is becoming increasingly clear that drugs targeting the epigenome may well form the cornerstone of future PTCL‐directed combination therapies. As this experience evolves, it will be incumbent on the scientific community to decipher, as best it can, the relationships between clinical activity of these combinations and the underlying epigenetic biology. In this fashion, it will be likely that very targeted epigenetic predicated platforms could emerge in a subtype directed manner.